SUBTYPES OF MUSCARINIC RECEPTORS

1983年召开的第一届M受体亚型研讨会， 是第一个探索多年来除了少数人之外都被忽视的领域的人 调查人员。作为针对一个实际问题的研究的结果 在治疗学中，毒碱受体亚型的概念 成为现实，整个研究领域被注入了活力，进入了快速 成长。自第一次研讨会以来的短短时间内，有3个亚型 根据新的和选择性的拮抗剂和 5种毒扁豆碱的序列、分布和偶联机制 已披露的受体。第八次座谈会将延续先例 通过增加我们对毒扁豆碱受体的基本知识 以及披露潜在的或已证明的新的激动剂和拮抗剂 治疗价值。主要目标是为 积极研究毒碱的个人之间的互动 受体功能和积极追求受体功能的研究者 随着技术的发展，受体亚型的身份和结构 来自分子克隆。将涵盖的广泛领域包括：1) M受体和M受体的分子药理学和生理学 与其他系统的相互作用；2)开发、药物化学和 新的选择性药物的临床方面，特别是在尊重 生殖和泌尿系统，心血管和肺功能， 3)对中枢M受体作用的新见解。 神经系统及其对阿尔茨海默病和老年人的憎恨 痴呆症。这次研讨会提供了一个独特的互动机会。 在生物化学家、生理学家、药理学家和神经学家之间 谁是正在采取的多学科方法的领导者 现场和年轻的研究人员和博士后研究员将出席 他们在海报会议上的工作。

The First Symposium of Subtypes of Muscarinic Receptors, held in 1983, was the first to probe a field ignored for years by all but a few investigators. As a result of research directed at a practical problem of therapeutics, the concept of subtypes of the muscarinic receptor became a reality and a whole field of research was energized into rapid growth. In the short time since the first symposium 3 subtypes have been clearly defined on the basis of new and selective antagonists and the sequences, distribution, and coupling mechanisms of 5 muscarinic receptors disclosed. The Eighth Symposium will continue the precedents set previously by increasing our basic knowledge of muscarinic receptors and disclosing new agonists and antagonists of potential or demonstrated therapeutic value. The major goals are to provide a forum for interaction between individuals who are actively studying muscarinic receptor function and investigators who are actively pursuing the identity and structure of receptor subtypes with technologies evolved from molecular cloning. The broad areas to be covered include: 1) molecular pharmacology and physiology of muscarinic receptors and interactions with other systems; 2) development, medicinal chemistry and clinical aspects of new, selective agents, particularly, with respect to genito-urinary systems, and cardiovascular and pulmonary function, and 3) new insights into the role of muscarinic receptors in the central nervous system and their revilance to Alzheimer's Disease and senile dementia. This symposium provides a unique opportunity for interaction between biochemists, physiologists, pharmacologists and neuroscientists who are the leaders in the multidisciplinary approach being taken in the field and young investigators and predoctoral fellows who will present their work in the poster sessions.